Topiramate Capsule, Extended Release
FDA Label NDC 70771-1317

1 label section · Submitted to the FDA by Zydus Lifesciences Limited · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Zydus Lifesciences Limited for the product Topiramate (NDC 70771-1317). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package Label.Principal Display Panel

NDC 70771-1315-3

Topiramate extended-release capsules, 25 mg

30 capsules

Rx only

25 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 01)

25 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 01)

NDC 70771-1316-3

Topiramate extended-release capsules, 50 mg

30 capsules

Rx only

50 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 02)

50 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 02)

NDC 70771-1317-3

Topiramate extended-release capsules, 100 mg

30 capsules

Rx only

100 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 03)

100 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 03)

NDC 70771-1858-3

Topiramate extended-release capsules, 200 mg

30 capsules

Rx only

200 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 04)

200 mg (709dd70b 24e1 435f 8373 02e6dd538b2c 04)

* Please review the disclaimer below.